Oren Livne

Oren Livne

Partner
Baker & McKenzie LLP

Biography

Oren Livne is a partner in the Corporate & Securities Practice Group and the Life Sciences Industry Group. Prior to beginning his law career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Practice Focus

Oren Livne counsels clients from startups to multinationals on a variety of corporate and transactional matters globally, including complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, mergers and acquisitions, and other intellectual property focused transactions. His clients include pharmaceutical, biotech, medical device, consumer product, and technology companies as well as private equity firms. Oren is a guest lecturer at New York University law and business classes and has authored several licensing and intellectual property articles.

Representative Legal Matters

  • Abbott in its collaboration with Supersapiens to advance Abbott's Libre Sense Glucose Sport Biosensor, which is designed to help athletes better understand the correlation between their glucose levels and their athletic performance. 
  • BeiGene in its exclusive license agreement with Singlomics (Beijing DanXu) Biopharmaceuticals to develop, manufacture and commercialize Singlomics’ investigational anti-COVID-19 antibodies globally outside of greater China.
  • CytoSorbents in its collaboration with Terumo Cardiovascular to commercialize CytoSorb® in ten US hotspot states under the FDA's Emergency Use Authorization for COVID-19.
  • CytoSorbents in its agreements with InvoSurg and Surgical Partners to commercialize CytoSorb® in the US Northeast, Mid-Atlantic, and Florida under the FDA's Emergency Use Authorization for COVID-19. 
  • Abbott in its agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions that combine Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management.
  • GSK Consumer Healthcare in its collaboration with Mammoth Biosciences to develop a rapid, handheld CRISPR-based test to detect novel coronavirus infections.
  • Galapagos in its collaboration with Ryvu Therapeutics focused on the discovery and development of novel small molecule drugs in inflammation.
  • Abbott in its collaboration with Insulet to integrate next-generation glucose sensing and automated insulin delivery technologies.
  • CytoSorbents in its agreement with China Medical System to bring CytoSorb® to mainland China to treat critically-ill patients with COVID-19 coronavirus infection. 
  • AbbVie in the expansion of its TriTAC discovery collaboration agreement with Harpoon.

Professional Honors

  • IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration 
  • Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
  • Notable Practitioner, IFLR 1000, 2020
  • Rising Star, Super Lawyers New Jersey, 2020
  • Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
  • Certified Licensing Professional, 2008-2020

Professional Associations and Memberships

  • New York State Bar Association
  • New Jersey State Bar Association
  • Licensing Executives Society

Admissions

  • New York~United States
  • New Jersey~United States
  • U.S. Patent and Trademark Office~United States

Education

  • New York University (MBA with distinction) (2012)
  • New York University School of Law (JD) (2012)
  • Rutgers University (BS Chemical Engineering with Highest Honors) (1996)

Languages

  • English